

References

- **Abbas N.A., John R.I., Webb M.C., Kempson M.E., Potter A.N., Price C.P., Vickery S., Lamb E.J.** : Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. *Clin Chem* 51: 2059–2066, 2005.
- **Achar S.A., Kundu S. and Norcross W.A.** : Diagnosis of acute coronary syndrome. *Am Fam Physician* 2005;72:1 19-126.
- **Agarwal R., Niesenson A.R., Battle D., et al.** : Prevalence, treatment and control of hypertension in hemodialysis patients in the United States. *Am. J. Med.* 2003; 115:291-297.
- **Alfakih K., Bloomer T., Bainbridge S., et al.** : A comparison of left ventricular mass between two-dimensional echocardiography using fundamental and tissue harmonic imaging and cardiac MRI in patients with hypertension. *Eur. J. Radiol* 2004;52: 103-109.
- **Amman K. and Ritz E.** : The heart in renal failure. A specific uremic cardiomyopathy. *J. Clin Bas Cardiol* 2001;4:109-1 13. 52.
- **Anwaruddin S., Lloyd-Jones D.M., Baggish A., Chen A., Krauser D., Tung R., Chae C., Januzzi J.L.** : Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. *J Am Coll Cardiol* 47: 91–97, 2006.
- **Apple F.S., Murakami M.M., Pearce L.A., Herzog C.A.** : Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. *Circulation* 106: 2941–2945, 2002.
- **Apple F.S., Murakami M.M., Pearce L.A., Herzog C.A.** : Multi-biomarker risk stratification of Nterminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. *Clin Chem* 50: 2279–2285, 2004.
- **Aulivola B., Hile C.N., Hamdan A.D., et al.** : Major lower extremity amputation: Outcome of a modem series. *Arch Surg* 2004;139: 395-399.
- **Aviles R.J., Askari A.T., Lindahl B., Wallentin L., Jia G., Ohman E.M., Mahaffey K.W., Newby L.K., Califf R.M., Simoons M.L., Topol E.J., Berger P., Lauer M.S.** : Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. *N Engl J Med* 346: 2047–2052, 2002.
- **Aytekin C., Boyvat F., Yagmurdur M.C., et al.** : endovascular stent placement in the treatment of upper extremity central venous obstruction in hemodialysis patients. *Eur. J. Radiol* 2004;49:81-85.
- **Azar R.R., Aoun G., Fram D.B., et al.** : Relation of C-reactive protein to extent and severity of coronary narrowing in patients with stable angina pectoris or abnormal exercise tests. *Am. J. Cardiol.* 2000;86:205-207.

- **Baigent C., Burbury K., and Wheeler D.** : Premature cardiovascular disease in chronic renal failure. *Lancet* 2000; 356:147-152.
- **Baigent C and Landry M.** : The results of the Study of Heart and Renal Protection. Presented at the American Society of Nephrology Renal Week, Denver, CO: November 20, 2010.
- **Banerjee A. and Davenport A.** : Changing patterns of pericardial disease in patients with end-stage renal disease. *Hemodialysis* 2006; 10:249.
- **Barri Y.M.** : Hypertension and Kidney Disease: A Deadly Connection. *Current Hypertension Reports* 2008; 10:39-45.
- **Bartalena L.** : The dilemma of non-thyroidal illness syndrome: To treat or not to treat? *J. Endocrinol Invest* 26: 1162, 2003.
- **Berger A.J., Duval S., Manske C., et al.** : Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. *Am. Heart J.* 2007;153:1064-1073.
- **Besarab A., Bolton W.K., Browne J.K., et al.** : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. *N. Engl. J. Med* 1998;339:584–590.
- **Bezante G.P., Chen X., Molinari G., et al.** : Left ventricular myocardial mass determination by contrast enhanced colour Doppler compared with magnetic resonance imaging. *Heart* 2005; 91:38-43.
- **Bhuriya R., Suying L., Chen S., Peter A., McCullough and George L.** : Plasma Parathyroid Hormone Level and Prevalent Cardiovascular Disease in CKD Stages 3 and 4: An Analysis From the Kidney Early Evaluation Program (KEEP). *Am J of Kidney Diseases*, Vol 53, No 4, Suppl 4 (April), 2009.
- **Bianchi S., Bigazzi R. and Compese V.M.** : Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. *Am. J. Kidney Dis* 1999;34:973-995.
- **Blacher J. and Safar M.E.** : Homocysteine, folic acid, B vitamins and cardiovascular risk. *J. Nutr. Health Aging* 2001; 5:196-199.
- **Boehme M., Kaehne F., Kuehne A., Bernhardt W., Schroder M., Pommer W., Fischer C., Becker H., Muller C., Schindler R.** : Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. *Nephrol Dial Transplant* 22: 2224–2229, 2007.
- **Braunwald E., Antman E.M., Beasley J.W., Califf R.M., Chaitlin M.D. et al** : ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). *J Am Coll Cardiol* 36: 970–1062, 2000.
- **Buemi S., Coppolino G., Russo S., et al.** : Real time electrocardiogram recording

during two different protocols of potassium hemodiafiltration. Preliminary results using a wearable health care system. *Am. J. Kidney Dis.* 2007;23 :311.

- **Busch M., Franke S. Muller A. et al.** : Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. *Kidney mt* 2004;66:338347.
- **Carrero J.J., Qureshi A.R., Axelsson J., Yilmaz M.I., Rehnmark S., Witt M.R., Barany P., Heimbürger O., Suliman M.E., Alvestrand A., Lindholm B., Stenvinkel P.** : Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. *J. Intern. Med.* 262: 690–701, 2007.
- **Carrero J.J., Yilmaz M.I., Lindholm B., Stenvinkel P.** : Cytokine dysregulation in chronic kidney disease: How can we treat it? *Blood Purif.* 26: 291–299, 2008.
- **Carrero J.J., Ortiz A., Qureshi A.R., Martin-Ventura J.L., Barany P., Heimbürger O., Marron B., Metry G., Snaedal S., Lindholm B., Egido J., Stenvinkel P., Blanco-Colio L.M.** : Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. *Clin. J. Am. Soc. Nephrol* 4: 110–118, 2009.
- **Cheung A.K., Sarnak M.J., Yan G. et al.** : Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. *Kidney mt* 2000;58: 353-362.
- **Chobanian A.V., Bakris G.L., Black H.R., et al.** : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 2003;42:1206-1252.
- **Cice G., Ferrara L., D'Andrea A., et al.** : Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. *J. Am. Coll. Cardiol* 2003;41 :1438-1444.
- **Clagett G.P., Sobel M. and Jackson M.R.** : Antithrombotic therapy in peripheral arterial occlusive disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126: 609-626.
- **Cohen M., Demers C., Gurfinkel E.P., et al.** : A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. *N. Eng. J. Med.* 1997;337:447-52.
- **Collins A.J., Li S., Gilbertson D.T. et al.** : Chronic kidney disease and cardiovascular disease in the Medicare population. *Kidney Int. Suppl* 2003;87:24-31.
- **Coresh J., Astor B.C., Greene T., et al.** : Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am. J. Kidney Dis.* 2003;41:112 .
- **Coyne D.W., Cheng S.C. and Delmez J.A.** : Bone disease. In: Daugirdas JT, Blake PG and Ing TS (eds), *Handbook of dialysis*, 4th edition. Lippincott Williams & Wilkins, Philadelphia, 2007, pp: 583-605.

- **Danesh J., Collins R., Appleby P. et al.** : Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. *JAMA* 1998;279:1477-1482.
- **Daugirdas J.T.** : Pathophysiology of dialysis hypotension: an update. *Am. J. Kidney Dis.* 2001;38(Suppl4): 11-17.
- **David S., Kumpers P., Seidler V., Biertz F., Haller H., Fliser D.** : Diagnostic value of Nterminal pro-B-type natriuretic peptide (NTProBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. *Nephrol Dial Transplant* December 18, 2007.
- **Davignon J. and Laskonen R.** : Low-density lipoprotein-independent effects of statins. *Curr Opin Lipidol* 1999; 10:543-559.
- **De Bakey M.E. and Glaeser D.H.** : Patterns of atherosclerosis: Effect of risk factors on recurrence and survival: Analysis of 11,890 cases with more than 25-year follow-up. *Am. J. Cardiol* 2000;85:1045-1053 .
- **De Filippi C.R., Thorn E.M., Aggarwal M., Joy A., Christenson R.H., Duh S.H., Jeudy J., Beache G.** : Frequency and cause of cardiac troponin T elevation in chronic hemodialysis patients from study of cardiovascular magnetic resonance. *Am J Cardiol* 100:885–889, 2007.
- **De Lima J.J., Vieira M.L., Lopes H.F. et al.** : Blood pressure and the risk of complex arrhythmia in renal insufficiency, hemodialysis and renal transplant patients. *Am. J. Hypertens* 1999;12:204-208.
- **De Loach S.S. and Mohler E.R.** : Peripheral Arterial Disease: A Guide for Nephrologists. *Clin. J. Am. Soc. Nephrol* 2007;6: 1-5.
- **De Mutsert R., Grootendorst D.C., Axelsson J., Boeschoten E.W., Krediet R.T., Dekker F.W.** : Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. *Nephrol Dial Transplant* 23: 2957–2964, 2008.
- **De Simone G.** : left ventricular geometry and hypotension in end-stage renal disease: a mechanical perspective. *J. Am. Soc. Nephrol* 2003;14:2421-2427.
- **Decker T, Kofoed-Enevoldsen A., Norgaard K. et al.** : Microalbuminuria Implications for micro and macro Vascular disease. *Diabetes Care* 1992; 15:1181-1191.
- **Descamps-Latscha B., Witko-Sarsat V., Nguyen-Khoa T., Nguyen A.T., Gausson V., Mothu N., London G.M., Jungers P.** : Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. *Am. J. Kidney Dis.* 45: 39–47, 2005.
- **Donauer J., Koiblin D., Bek M., et al.** : Ultrafiltration profiling and measurement of relative blood volume as strategies to reduce hemodialysis-related side effects. *Am. J. Kidney Dis.* 2000; 36:115-123.

- **Dormandy J.A. and Rutherford R.B. :** Management of peripheral arterial disease (PAD). *J. Vase Surg* 2000;31: 51-5296.
- **Eggers P.W., Gohdes D. and Pugh J.:** Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. *Kidney Int* 1999;56: 1524-1533.
- **Ejerblad S., Eriksson I., Johansson H. :** Uraemic arterial disease. An experimental study with special reference to the effect of parathyroidectomy. *Scand J Urol Nephrol* 13:161-169, 2008.
- **Fahie-Wilson M.N., Carmichael D.J., Delaney M.P., Stevens P.E., Hall E.M., Lamb E.J.:** Cardiac troponin T circulates in the free, intact form in patients with kidney failure. *Clin Chem* 52: 414–420, 2006.
- **Fellstrom B.C., Jardine A.G., Schmieder R.E. et al. :** Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *N Engl J Med.* 2009; 360:1395-407.
- **Finkestein JO: The metabolism of homocysteine:** pathways and regulation. *EurJPediatr* 1998;157:S40-S44.
- **Fishbane S., Bucala R., Pereira B.J. et al. :** Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. *Kidney Int.* 1997; 52:1645-1650.
- **Foley R.N., Herzog C.A. and Cottins A.J. :** Smoking and cardiovascular outcomes in dialysis patients: The united States Renal Data System Wave 2 Study. *Kidney Int.* 2003;63:1462-1467.
- **Foley R.N. Murray A.M., Li S. et al. :** Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the united States Medicare population, 1998 to 1999. *J. Am Soc. Nephrol* V 2005; 16:489-495.
- **Foley R.N., Li S., Liu J. et al. :** The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. *J. Am. Soc. Nephrol* 2005a; 16:210-2 18.
- **Fouque D., Kalantar-Zadeh K., Kopple J., Cano N., Chauveau P., Cuppari L., Franch H., Guarnieri G., Ikizler T.A., Kaysen G., Lindholm B., Massy Z., Mitch W., Pineda E., Stenvinkel P., Trevinho-Becerra A., Wanner C. :** A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. *Kidney Int* 2008.
- **Ganau A., Devereux R.B., Roman M.J. et al. :** Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. *J. Am. Coil Cardiol* 1992; 19:1550-1558.
- **Garibotto G., Russo R., Sofia A., Ferone D., Fiorini F., Cappelli V., Tarroni A., Gandolfo M.T., Vigo E., Valli A., Arvigo M., Verzola D., Ravera G., Minuto F. :** Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases. *Kidney Int.* 74: 937–945, 2008.
- **Genovesi S. Rivera R., Fabbrini P. et al. :** Dynamic QT, interval analysis in uraemic patients receiving chronic haemodialysis. *Hypertens* 2003; 21:1921-1926.

- **George S.K. and Singh A.K.** : Current markers of myocardial ischemia and their validity in end stage renal disease. *Curr Opin Nephrol Hypertens* 1999;8:71-722.
- **Giachelli C.M.** : Vascular calcification mechanisms. *J. Am. Soc. Nephrol* 2004; 15:2959-2964.
- **Go A.S., Chertow G.M., Fan D. et al.** : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N. Engl. J. Med* 2004;351 :1296-1306.
- **Goodman W.G., Goldin L., Kuizon B.D. et al.** : Coronary-artery calcification in young adults with endstage renal disease who are undergoing dialysis. *N. Engl. J. Med* 2000; 342:1478 -1483.
- **Gradaus F., Ivens K., Peters A.J. et al.** : Angiographic progression of coronary artery disease in patients with endstage renal disease. *Nephrol Dial Transplant* 2001;16:1 198-1202.
- **Grech E.D. and Ramsdale D.R.** : Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. *BMJ* 2003; 326:1259-1261.
- **Guerin A.P., Adda H., London G.M. et al.** : Cardiovascular disease in renal failure. *Minerva Urol Nefrol* 2004; 56:279-288.
- **Guerra A., Raynaud A., Beyssen B. et al.** : Arterial percutaneous angioplasty in upper limbs with vascular access devices for hemodialysis. *Nephrol dial transplant* 2002; 17:843-851.
- **Gunukula S.R. and Spodick D.H.** : Pericardial disease in renal patients *Semin Nephrol* 2001; 21:52.
- **Henriksson A.E. and Bergqvist D.** : steal syndrome of the hemodialysis vascular access: Diagnosis and treatment. *J. Vasc Access* 2004; 5:62-68.
- **Herrmann S.M., Whatling C., Brand E. et al.** : Polymorphisms of the human matrix gla protein (MOP) gene, vascular calcification, and myocardial infarction. *Arterioscler Thromb Vase Biol* 2000; 20:23 86- 2393.
- **Herzog C.A., Ma J.Z. and Collins A.J.** : Comparative survival of dialysis patients in the united states after coronary angioplasty, coronary artery stenting, and coronary artery by surgery and impact of diabetes. *Circulation* 2002; 106:2207-2211.
- **Himmelfarb J., Chuang P. and Schulman G.** : Hemodialysis. In: Brenner BM (ed.), Brenner and Rector's *The Kidney*, 8th ed. W.B. Saunders, Philadelphia, 2008, pp : 1957-2006.
- **Hirsch A.T., Criqui M.H. and Treat-Jacobson D.** : Peripheral arterial disease detection, awareness, and treatment in primary care. *JAMA* 2001;286: 1317-1324.
- **Hongo R.H., Ley J., Dick S.E. et al.** : The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. *J. Am. Coil Cardiol* 2002; 40:231237.
- **Horl W.H.** : Iron therapy for renal anemia: how much needed, how much harmful?.

Pediatr Nephrol 2007; 22:48089.

- **Hunold P., Vogt F.M., Heemanfl U.W., et al.** : Myocardial mass and volume measurement of hypertrophic left ventricles by MRI-study in dialysis patients examined before and after dialysis. *J. Cardiovasc Magn Reson* 2003;5:553-561.
- **Ivanovski O., Szumila D., Nguyen-Khoa T., Ruellan N., Phan O., Lacour B., Descamps-Latscha, Druke T.B. and Massy Z.** : The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. *Kidney Int.* 67: 2288–2294, 2005.
- **Jaar B.G., Astor B.C., Berns J.S., et al.** : Predictors of amputation and survival following lower extremity revascularization in hemodialysis patients. *Kidney Int.* 2004; 65: 613-620.
- **Jacoby J.S., Mohier E.R. and Rader D.J.** : Non invasive atherosclerosis imaging for predicting cardiovascular events and assessing therapeutic interventions. *Curr Atheroscler Rep* 2004;6:20-26.
- **Januzzi J.L., Camargo C.A., Anwaruddin S., Baggish A.L., Chen A.A., Krauser D.G., Tung R., Cameron R., Nagurney J.T., Chae C.U., Lloyd- Jones D.M., Brown D.F., Foran-Melanson S., Sluss P.M., Lee-Lewandrowski E., Lewandrowski K.B.** : The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. *Am J Cardiol* 95: 948–954, 2005.
- **Jindal R.M. and Hjelsmesaeth J.** : Impact and management of post- transplant diabetes. *Transplantation* 2000;70:558-563.
- **Jofre R., Rodriguez-Benitez F., Lopez-Gomez J.M. et al.** : Inflammatory syndrome in patients on hemodialysis. *J. Am. Soc. Nephrol* 2006; 17 (suppl 3) : 5274-5280.
- **Johnson D.W.** : Evidence-based guide to slowing the progression of early renal insufficiency. *Intern Med. J.* 2004; 34:50-57.
- **Johnson D W and Mathew T:** Managing chronic kidney disease. *Med Today* 2007;8:37-45.
- **Johnson N., Dargie H., Jardine A., et al.** : Diagnosis and Treatment of coronary artery disease in patients with chronic kidney disease. *J Am Soc Nephrol* 2008;94:1080-1088.
- **Kamycheva E., Sundsfjord J., Jorde R.** : Serum parathyroid hormone levels predict coronary heart disease: The Tromso Study. *Eur J Cardiovasc Prev Rehabil* 11:69-74, 2004.
- **Kasiske B.L., Chakkera H.A. and Roel J.** : Explained and unexplained ischaemic heart disease after renal transplantation. *J. Am. Soc. Nephrol* 2000 11:1735-1743.
- **Ketteter M., Gross M.L. and Ritz E.** : Calcification and cardiovascular problems in renal failure. *Kidney Int. Suppl* 2003; 94 : 5120 -5127.
- **Khan N.A., Hemmelgarn B.R., Tonelli M., Thompson C.R., Levin A.** : Prognostic value of troponin T and I among asymptomatic patients with end-stage

renal disease: A metaanalysis. *Circulation* 112: 3088–3096, 2005.

- **Kidney Disease Outcome Quality Initiative (K/DOQI)** : K/DOQI clinical practice guidelines for Cardiovascular disease in dialysis patients. *Am. J. Kidney Dis.* 2005; 45(Suppl 3) : 51-5153.
- **Kidney Disease Outcome Quality Initiative (K/DOQI)** : K/DOQI clinical practice guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. *Am. J. Kidney Dis.* 2006; 48(Suppl 1): 52-590.
- **Kidney Disease Outcome Quality Initiative (K/DOQI)** : K/DOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. *Am. J. Kidney Dis.* 2006a; 47(Suppl 3):511-5145
- **Kim D.K., Kim H.J., Han S.H., Lee J.E., Moon S.J., Kim B.S., Kang S.W., Choi K.H., Lee H.Y. and Han D.S.** : Chlamydia pneumoniae accompanied by inflammation is associated with the progression of atherosclerosis in CAPD patients: A prospective study for 3 years. *Nephrol Dial Transplant* 23: 1011–1018, 2008.
- **Klinkhardt U., Kirchmaier C.M., Westrup D. et al.** : Ex vivo-vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SRI 21 566A. *Clin Pharma col Ther* 2000;67:305-313.
- **Koc M, Richards HB, Bihorac A, Ross EA, Schold JD, Segal MS:** Circulating endothelial cells are associated with future vascular events in hemodialysis patients. *Kidney Int* 67: 1079–1083, 2005.
- **Konner K., Nonnast D.B. and Ritz E.** : The arteriovenous fistula. *J. Am. Soc. Nephrol* 2003; 14:1669-1680.
- **Kronenberg F., Knig P., Lhotta K. et al.** : Lipoprotein [a] phenotype- associated decrease in lipoprotein[a] plasma concentrations after renal transplantation. *Arterioscier Thromb* 1994; 14:1399-1404.
- **Kudo Y., Yamasaki F., Dot T. et al.** : Clinical significance of low voltage in asymptomatic patients with pericardial effusion free of heart disease. *Chest* 2003; 124:2064.
- **Lahoz C., Mostaza J.M., Mantilla M.T. et al.** : Achievement of therapeutic goals and utilization of evidence-based cardiovascular therapies in coronary heart disease patients with chronic kidney disease. *Am. J. Cardiol* 2008;101 :1098-1102.
- **Lee J.A., Kim D.H., Yoo S.J., Oh D.J., Yu S.H., Kang E.T.** : Association between serum N-terminal pro-brain natriuretic peptide concentration and left ventricular dysfunction and extracellular water in continuous ambulatory peritoneal dialysis patients. *Perit Dial Int* 26: 360–365, 2006.
- **Leskinen Y., Salenius J.P., Lehtimaki T. et al.** : The prevalence of peripheral arterial disease and medial artery calcification in patients with chronic renal failure: Requirements for diagnostics. *Am. J. Kidney Dis.* 2002;40:472479.
- **Levin A., Djurdjev O., Barrett B. et al.** : Cardiovascular disease in patients with

chronic kidney disease :Getting to the heart of the matter. *Am. J. kidney Dis.* 2001; 38:398-1407.

- **Lincoff A.M., Calzff R.M. and Topol E.J.** : Platelet Glycoprotein IIb/ IIIa receptor blockade in coronary artery disease. *J. Am. Coil Cardiol* 2000;35:1 103-1115.
- **Little R.R., Tennill A.L., Rohifing C.L.** : Can Glycohemoglobin Be Used to Assess Glycemic Control in Patients with Chronic Renal Failure?. *Clinical Chemistry* 2002;48:784-786.
- **Liu M., Takahashi H., Morita Y. et al.** : Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in hemodialysis patients. *Nephrol Dial Transplant* 2003;18:563.
- **Liu Y., Berthier-Schaad Y., Fallin M.D., Fink N.E., Tracy R.P., Klag M.J., Smith M.W., Coresh J.** : IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. *J. Am. Soc. Nephrol* 17: 863–870, 2006.
- **Locatelli F., Del Vecchio L. and Pozzoni F.** : “The Importance of Early Detection of Chronic Kidney Disease”, *Nephrol Dial Transplant* 2002;17 (Suppl 1) : S2-S7.
- **Locatelli F., Aijama P., Barany F., et al.** : European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. *Nephrol Dial Transplant* 2004; 19 (Suppl 2): 51-547.
- **London G.M.** : Heterogeneity of left ventricular hypertrophy, does it have clinical implications? *Nephrol Dial Transplant* 1998; 13:17-19.
- **London G.M., Pannier B., Marchais S.J. et al.** : calcification of the aortic valve in the dialyzed patient. *J. Am. Soc. Nephrol* 2000;1 1:778-783.
- **London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., Adda H.** : Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. *Nephrol Dial Transplant* 18: 1731–1740, 2003.
- **London G.M., Pannier B., Agharazii M. et al.** : Forearm reactive hyperemia and mortality in end-stage renal disease. *Kidney Int.* 2004;65:700-704.
- **Longenecker J.C., Coresh J., Powe N.R. et al.** : Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. *J. Am. Soc. Nephrol* 2002;13:1918 -1927.
- **Lyoda M., Ajiro Y., Sato K. et al.** : A case of refractory uremic pleuropericarditis5uess corticosteroid treatment. *Clin. Nephrol* 2006;65 :290.
- **Mackrell P.J., Cull D.L. and Carston C.G.** : Hemodialysis access: placement and management of complication. In: Hallett JW, Mills JL, Earnshaw JJ and Reekers JA.(eds), *Comprehensive vascular and endovascular surgery*, Istedition. Mosby, Philadelphia, 2004, pp:361-390.
- **Madsen L.H., Ladefoged S., Corell P., Schou M., Hildebrandt P.R., Atar D.** : N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. *Kidney Int* 71: 548–554, 2007.

- **Mallamaci F., Zoccali C. and Tripepi G.** : Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. *Kidney Int.* 2002;61:609-614.
- **Mancini E., Mambelli F., Irpinia M., et al.** : Prevention of dialysis hypotension episodes using fuzzy logic control system. *Nephrol Dial Transplant* 2007; 22: 1420-1427.
- **Mangan S.H., Campenhout A.V., Rush C., Golledge J.** : Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor- α associated with induction of angiopoietin-2. *Cardiovasc Res* 76: 494–505, 2007
- **Mantovani A., Garlanda C., Bottazzi B., Peri G., Doni A., Martinez de la Torre Y., Latini R.** : The long pentraxin PTX3 in vascular pathology. *Vascul Pharmacol* 45: 326–330, 2006.
- **Mark P.B., Stewart G.A., Gansevoort R.T., Petrie C.J., McDonagh T.A., Dargie H.J., Rodger R.S., Jardine A.G.** : Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. *Nephrol Dial Transplant* 21: 402–410, 2006.
- **Marckmann P., Skov L., Rossen K. et al.** : Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. *J. Am. Soc. Nephrol* 2006; 17:2359-2362.
- **Marrs J.C., Saseen J.J.** : Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis. *Pharmacotherapy*. 2010; 30:823-9.
- **Marso S.P., Gimpie L.W., Philbrick J.T. et al.** : Effectiveness of percutaneous coronary interventions to prevent recurrent coronary events in patients on chronic hemodialysis. *Am. J. Cardiol* 1998;82:378-380.
- **McCullough P.A., Nowak R.M., McCord J., Hollander J.E., Herrmann H.C., Steg P.G., Duc P., Westheim A., Omland T., Knudsen C.W., Storrow A.B., Abraham W.T., Lamba S., Wu A.H., Perez A., Clopton P., Krishnaswamy P., Kazanegra R., Maisel A.S.** : B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. *Circulation* 106: 416-422, 2002.
- **McGee S.R. and Boyko E.J.** : Physical examination and chronic lower- extremity ischemia : A critical review. *Arch Intern Med* 1998;158: 135 7-13 64.
- **McGregor E., Stewart G., Rodger R.S. et al.** : Early echocardiographic changes and survival following renal transplantation. *Nephrol Dial Transplant* 2000; 15:93-98.
- **McIntyre C.W., Lambie S.H. and Fluck R.J.** : Biofeedback controlled hemodialysis reduces symptoms and increases both hemodynamic tolerability and dialysis adequacy in non-hypotension prone stable patients. *Clin. Nephrol* 2003;60:105-112.
- **McMahon L.P. and Parfrey P.S.** : Cardiovascular Aspect of Chronic Kidney

- Disease. In: Brenner BM. (ed), Brenner and Rector's The Kidney, 8th ed. W. B. Saunders, Philadelphia, 2008, pp: 1697-1727.
- **Mhairi K.S., Lisa D., Maarten W.T., et al.** : Length of interdialytic interval influences serum calcium and phosphorus concentrations Nephrol Dial Transplant 2005; 20: 1643-1646.
 - **Miyazaki H., Matsuoka H., Itabe H. et al.** : Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 2000; 101:1002±1006.
 - **Mohler E.R.** : Peripheral arterial disease: Identification and implications Arch Intern Med 2003;163 : 2306-7314.
 - **Morales M.A., Gremigni C., Dattolo F. et al.** : Signal averaged ECG abnormalities in haemodialysis patients. Role of dialysis. Nephrol Dial Transplant 1998;13: 668-673.
 - **Morena M., Terrier N., Jaussent I., Leray-Moragues H., Chalabi L., Rivory J.P., Maurice F., Delcourt C., Cristol J.P., Canaud B., Dupuy A.M.** : Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J. Am. Soc. Nephrol 17:262–270, 2006.
 - **Morris S.T.W., Galiatsou E., Stewart G.A. et al** : QT dispersal before and after dialysis. J. Am. Soc. Nephrol 1999;10:160_163.
 - **Muntinghe F.L., Verduijn M., Zuurman M.W., Grootendorst D., Carrero J.J., Qureshi A.R., Luttropp K., Nordfors L., Brandenburg V., Stenvinkel S., Schalling M., Boeschoten E.W., Krediet R.T., Navis G., Dekker F.W.** : C-chemokine receptor 5 deletion (CCR5_32) polymorphism protects against the increased mortality rate seen in dialysis patients with chronic inflammation. J. Am. Soc. Nephrol 20: 1641–1649, 2009.
 - **Murphy S.W., Foley R.N. and Parfrey P.S.** : Screening and treatment for cardiovascular disease in patients with chronic renal disease. Am. Kidney Dis. 1998 (Suppl 3) :5184:5199.
 - **Nakamoto H., Suzuki T., Sugahara S. et al.** : Successful use of thoracoscopic pericardiectomy in elderly patients with massive pericardial effusion caused by uremic pericarditis. Am. J. Kidney Dis. 2001; 37: 1294.
 - **Nakamura S., Ogata C., Aihara I.V. et al** : QTc dispersion in hemodialysis patients with cardiac complications. Nephrology 2005;10: 113-118.
 - **Nanayakkara P.W., Van Guldener C., Ter Wee P.M., Scheffer P.G., Van Ittersum F.J., Twisk J.W., Teerlink T., Van Dorp W., Stehouwer C.D.** : Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: Results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 167: 1262–1270, 2007.
 - **Narita M., Kurihara T., Sindok T. et al.** : Characteristics of myocardial ischemia in patients with chronic renal failure and its relation to cardiac sympathetic

activity. *Kaku Igaku* 1999;36:979-987.

- **Neumann J, Ligtenberg G, Klein II, et al** : Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. *Kidney mt* 2004;65:168 —1576.
- **Neville R.F., Abularrage C.J., White P.W. et al.** : Venous hypertension associated with arteriovenous hemodialysis access. *Semin Vase Surg* 2004; 17:50-56.
- **O'Hare A.M.** : High prevalence of peripheral arterial disease in persons with renal insufficiency: Results from the National Health and Nutrition Examination Survey. *Circulation* 2004; 109:320-323.
- **O'Hare A.M., Bacchetti P., Segal M. et al.** : Factors associated with future amputation among patients undergoing hemodialysis :Results from the dialysis morbidity and mortality study waves 3 and 4. *Ant. J. Kidney Dis.* 2003 ;4 1:162-170.
- **Oberg B.P., McMEnamin E., Lucas F.L., McMonagle E., Morrow J., Ikizler T.A., Himmelfarb J.** : Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. *Kidney Int.* 65: 1009-1016, 2004.
- **Parekh R.S., Plantinga L.C., Kao W.H., Meoni L.A., Jaar B.G., Fink N.E., Powe N.R., Coresh J., Klag M.J.** : The association of sudden cardiac death with inflammation and other traditional risk factors. *Kidney Int.* 74: 1335–1342, 2008.
- **Perna A. and Remuzzi G.** : Abnormal permeability to proteins and glomerular lesions: A meta-analysis of experimental and human studies. *Am. J. Kidney Dis.* 1996; 27:34-41.
- **Pingitore A., Landi P., Taddei M.C., Ripoli A., L'Abbate A., Iervasi G.** : Triiodothyronine levels for risk stratification of patients with chronic heart failure. *Am. J. Med* 118: 132–136,2005.
- **Pruefer D., Scalia R. and Lefer A.M.** : Homocysteine provokes leukocyte endothelium interaction by down regulation of nitric oxide *Gen Pharmac* 1999; 33:487-498
- **Raj D.S., Carrero J.J., Vallabh O.S., Qureshi A.R., Barany P., Heimbürger M., Lindholm B., Ferguson J., Moseley P.L., Stenvinkel P.** : Soluble CD14 levels, interleukin-6 and mortality among prevalent hemodialysis patients. *Am. J. Kidney Dis.*2009.
- **Regensteiner J.G., Ware J.E., McCarthy W.J. et al.** : Effect of cilostazol on treadmill walking, community-based walking ability, and healthrelated quality of life in patients with intermittent claudication due to peripheral arterial disease: Meta-analysis of six randomized controlled trials. *J. Am. Geriatr Soc.* 2002; 50:1939 1946.
- **Rigatto C. and Parfrey P.S.** : Arrhythmia in Hemodialysis Patients. In: Fine RN and Nissenson AR (eds), *Handbook of dialysis therapy*, 4th edition. Saunders,

Philadelphia, 2008,pp:426-444.

- **Roberts M.A., Fernando D., Macmillan N. et al.** : Single and serial measurements of cardiac troponin I in asymptomatic patients on chronic hemodialysis. *Clin Nephrol* 2004;61:40-46.
- **Rocco M.V., Yan G., Heyka R.J. et al.** : Risk factors for hypertension in chronic hemodialysis patients: baseline data from the 1-IEMO study. *Am. J. Nephrol* 2001, 21:280-288.
- **Rocco M.V. and Ikizler T.A.** : Nutrition. In: Daugirdas JT, Blake PG and Ing TS (eds), *Handbook of dialysis*, 4th edition. Lippincott Williams & Wilkins, Philadelphia, 2007, pp:462-48 1.
- **Rossert J., Fouqueray B. and Boa J.J.** : Anemia management and the delay of chronic renal failure progression. *J. Am. Soc. Nephrol/* 2003; 14:173-177.
- **Saleh F.N., Schirmer H., Sundsfjord J. et al.** : Parathyroid hormone and left ventricular hypertrophy. *Eur Heart J* 24:2054-2060, 2003.
- **Salmela K. and Ahonen J.** : Peripheral arterial disease as a predictor of outcome after renal transplantation. *Transplant Int.* 199811 (Suppl 1): 5140-5143.
- **Santoro A., Mancini E., Fontanazzi F. et al.** : Potassium profiling in acetate free biofiltration. *Contrib Nephrol* 2002; 137:260-267.
- **Santoro A., Mancini E., Gaggi R., et al.** : Electrophysiological response to dialysis: the role of dialysate potassium content and profiling. *Contrib Nephro/* 2005;149:295-305.
- **Santoro A., Mancinil E., London G. et al.** : Patients with complex arrhythmias during and after hemodialysis suffer from different regimens of potassium removal. *Nephrol Dial Transplant* 2008; 23:1415-1421.
- **Saseen J.** : Exploring Clinical Controversies in Dyslipidemia-Combination Therapy, Chronic Kidney Disease, and New Evidence.2011; 1-4.
- **Satyan S., Light R.P., Agarwal R.** : Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. *Am J Kidney Dis* 50: 1009–1019, 2007.
- **Schiffrin E.L., Lipman M.L. and Mann J.F.E.** : Chronic Kidney Disease: Effects on the Cardiovascular System. *Circulation* 2007; 116:85-97
- **Schinke T., Amendt C., Trindi A. et al.** : The serum protein alpha2HS glycoprotein/fetuin inhibits apatite formation in vitro and mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. *J. Biol Chem* 1996; 271:20789-20796.
- **Schlieper G., Kruger T., Djuric Z., Damjanovic T., Markovic N., Schurgers L.J., Brandenburg V.M., Westenfeld R., Dimkovic S., Ketteler M., Grootendorst D.C., Dekker F.W., Floege J., Dimkovic N.** : Vascular access calcification predicts mortality in hemodialysis patients. *Kidney Int.* 74: 1582–1587, 2008.

- **Schmidt R., Roehrer O., Hicksteins H. et al.** : Prevention of hemodialysis-induced hypotension by biofeedback control of ultrafiltration and infusion. *Nephrol Dial Transplant* 2001;16:595-603.
- **Schnuelle F., Lorenz D., Trede M et al.** : Impact of renal cadaveric transplantation on survival in end-stage renal failure: Evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. *J. Am. Soc. Nephrol* 1998; 9:2135-2141.
- **Schroder C.H.** : European Pediatric Peritoneal Dialysis Working Group. The management of anemia in pediatric peritoneal dialysis patients. *Pediatr Nephrol* 2003; 18:805-809.
- **Schwarz U., Buzelto M., Ritz E. et al.** : Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. *Nephrol Dial Transplant* 2000; 15:218-223.
- **Sela S., Shurtz-Swiriski R., Cohen-Mazor M., Mazor R., Chezdar J., Shapiro G., Hassan K., Skolnik G., Geron R., Kristal B.** : Primed peripheral polymorphonuclear leucocyte: A culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. *J. Am. Soc. Nephrol* 16: 2431–2438, 2005.
- **Selvin E. and Erlinger T.P.** : Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999-2000. *Circulation* 2004;110:738-743.
- **Severi S., Cavalcanti S., Mancini E. et al.** : Heart rate response to hemodialysis and changes in potassium and calcium levels. *J. Nephrol* 2001;14: 488-496.
- **Sharma R, Pellerin D, Gaze D, et al** :Dobutamine stress echocardiography and the resting but not exercise electrocardiography predict severe coronary artery disease in renal transplant candidates . *Nephrol Dial Transplant* 2006; 20 :2207-14.
- **Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP):** randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. *Am Heart J.* 2010;160:785-794.
- **Siems W., Carluccio F., Grune T. et al.** : Elevated serum concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to severity of renal anemia. *Clin Nephrol* 2002; 58:(Suppl 1):520-525.
- **SIGN** : Diagnosis and management of chronic kidney disease: A national clinical guideline, 2008 Scottish Intercollegiate Guidelines Network.
- **Sommerer C., Giannitsis E., Schwenger V., Zeier M.** : **Cardiac biomarkers in haemodialysis patients:** The prognostic value of aminoterminal pro-B-type natriuretic peptide and cardiac troponin T. *Nephron Clin Pract* 107: c77–c81, 2007.
- **Speckman R.A., Frankenfield D.A., Roman S.H. et al.** : Diabetes is strongest risk factor for lower extremity amputation in new hemodialysis patients. *Diabetes Care*

2004; 27: 2198-2203.

- **Stack A.G.** : Coronary artery disease and peripheral vascular disease in chronic kidney disease: An epidemiologic perspective. *Cardiol Clin* 2005;23: 285-298.
- **Stenvinkel P.** : Endothelial dysfunction and inflammation: Is there a link? *Nephrol Dial Transpl* 16: 1968–1971, 2001.
- **Stenvinkel P. and Carrero J.J.** : Persistent inflammation as acatalyst for other risk factors in CKD .*Clin J Am Soc Nephrol* 4 :549-555, 2009.
- **Stenvinkel P., Heimbürger O., Jogestrand T.** : Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: Association with *Chlamydia pneumoniae* seropositivity. *Am. J. Kidney Dis.* 39: 274–282, 2002.
- **Stenvinkel P., Carrero J.J., Axelsson J., Lindholm B., Heimbürger O., Massy Z:** Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? *Clin J. Am. Soc. Nephrol* 3: 505–521,15:953-960, 2008.
- **Stephenson J.M., Kenny S., Stevens L.K. et al.** : Proteinuria and mortality in diabetes: The WHO Multinational Study of Vascular Disease in Diabetes. *Diabetes Med* 1994; 12:149-155.
- **Straver B., de Vries P.M.J.M., Donker A.J.M. et al.** : The effect of profiled hemodialysis on intradialytic hemodynamics when a proper sodium balance is applied. *Blood Purif* 2002; 20:364-369 .
- **Strippoli G.F., Navaneethan S.D., Johnson D.W. et al.** : Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. *BMJ*2008;336:645-651.
- **Suliman M., Heimbürger O., Barany P., Anderstam B., Pecoits-Filho R., Ayala E.R., Fehrman I., Lindholm B., Stenvinkel P.:** Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. *J. Am. Soc. Nephrol* 14: 1614–1622, 2003.
- **Suliman M., Qureshi A.R., Heimbürger O., Lindholm B., Stenvinkel P. :** Soluble adhesion molecules in end-stage renal disease: A predictor of outcome. *Nephrol Dial Transpl* 21:1603–1610, 2006.
- **Suliman M.E., Garcia-Lopez E., Anderstam B., Lindholm B., Stenvinkel P. :** Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease. *Adv Clin Chem* 46: 217–262, 2008.
- **Swynghedauw B.** : Molecular mechanisms of myocardial remodeling. *Physiol Rev* 1999; 79:215-262.
- **Tatematsu S., Wakino S., Kanda T., Homma K., Yoshioka K., Hasegawa K., Sugano N., Kimoto M., Saruta T., Hayashi K.:** Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease. *J. Am. Soc. Nephrol* 18: 741–749, 2007.
- **Taylor S.M., Kallbaugh C.A., Blackhurst D.W. et al.** : Preoperative clinical

factors predict postoperative functional outcomes after major lower limb amputation: An analysis of 553 consecutive patients. *J. Vasc Surg* 2005; 42 : 227-235.

- **Tepel M., Vander G.M., Schwarzfeld C. et al.** : Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. *N. Engl. J. Med* 2000;343:180-184.
- **Thomas M.C., Baynes J.W., Thorpe S.R., et al.** : The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. *Curr Drug Targets* 2005;6:453-474.
- **Toschi V., Gallo R., Lettino M. et al.** : Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. *Circulation*. 1997; 95:594-599.
- **Trevisan R., Dodesini A.R. and Lepore G.** : Lipids and renal disease. *J. Am. Soc. Nephrol* 2006; 17(suppl 2): 5145-5147.
- **Trivieri M.G., Oudit G.Y., Sah R., Kerfant B.G., Sun H., Gramolini A.O., Pan Y., Wickenden A.D., Croteau W., Morreale de Escobar G., Pekhletski R., St Germain D., MacLennan D.H., Backx P.H.** : Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. *Proc Natl Acad Sci U S A* 103:6043–6048, 2006.
- **Tzamaloukas A.H., Leehey D.J. and Friedman E.A.** : Diabetes. In: Daugirdas JT, Blake PG and Ing TS (eds), *Handbook of dialysis*, 4th edition. Lippincott William & Wilkins, Philadelphia, 2007, pp:490-507.
- **United States Renal Data System 2003** : Annual Data Report. Excerpts from the united states renal data system: atlas of end-stage renal disease in the United States. *Am. J. Kidney Dis* 2003;42 (Suppl5) :51-5230.
- **Van der Sande F.M., Kooman J.P. and Leunissen K.M.L.** : Strategies for improving hemodynamic stability in cardiac compromised dialysis patients. *Nephrol Dial Transplant* 2000; 15: 1746-1748.
- **Van S.F., Ramasaniy R., Naka I. et al.** : Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. *Circ Res* 2003; 93: 1159-1169.
- **Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lamiere N:** Chronic kidney disease as a cause of cardiovascular morbidity and mortality. *Nephrol Dial Transpl* 20:1048–1056, 2005.
- **Vivekananthan D.P., Penn M.S., Sapp S.K. et al.** : Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomized trials. *Lancet* 2003 ;3 61:2017-2023.
- **Wang A.Y. and Lai K.** : Use Of Cardiac Biomarkers in End Stage Renal Disease. *J Am Soc Nephrol* 19: 1643-1652,2008.
- **Wang A.Y., Lam C.W., Yu C.M., Wang M., Chan I.H., Lui S.F., Sanderson J.E.** : Troponin T, left ventricular mass, and function are excellent predictors of cardiovascular congestion in peritoneal dialysis. *Kidney Int* 70: 444–452, 2006.
- **Wang A.Y., Lam C.W., Yu C.M., Wang M., Chan I.H., Zhang Y., Lui S.F., Sanderson J.E.** : N-terminal pro-brain natriuretic peptide: an independent risk

predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. *J Am Soc Nephrol* 18: 321–330, 2007.

- **Ward R.A., Ouseph R. and McLejsh K.R.** : Effects of high-flux hemodialysis on oxidant stress. *Kidney Int.* 2003; 63:353-359.
- **Weiner D.E., Nicholls A.J. and Sarnak M.J.** : Cardiovascular disease. In: Daugirdas JT, Blake PG and Ing TS (eds), *Handbook of dialysis*, 4th edition. Lippincott Williams &Wilkins, Philadelphia, 2007, pp:626-646.
- **Weiss G. and Goodnough L.T.** : Anemia of chronic disease. *N. Engl. J. Med* 2005; 352:1011-1023.
- **Werner N. and Nickenig G.** : Clinical and therapeutical implications of EPC biology in-atherosclerosis. *J. Cell Mol Med* 2006; 10:318-332.
- **Wheeler D.C.** : Cardiovascular complications of chronic kidney disease. *Medicine* 2007; 35 : 453-456.
- **Wiese P. and Nonnast B.** : color Doppler use in dialysis access. *Nephrol-Dial transplant.*2004;19:1956-1963.
- **Wizemann V.** : Coronary artery disease in dialysis patients. *Nephron* 1996; 74:642-651.
- **Wongpraparui N., Apiyasawat S., Crespo G. et al.** : Determinants of progression of aortic stenosis in patients aged > or =40 years. *Am. J. Cardiol* 2002;89:350-352.
- **Wood J.E. and Mahnensmith R.L.** : Pericarditis associated with renal failure. Evolution and management. *Semin Dial* 2001;14:61-66.
- **Wu A.H., Jaffe A.S., Apple F.S., Jesse R.L., Francis G.L., Morrow D.A., Newby L.K., Ravkilde J., Tang W.H., Christenson R.H., Cannon C.P.** : National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. *Clin Chem* October 22, 2007.
- **Xu J., Li G., Wang P. et al.** : Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. *J. Clin Invest* 2005;1 15:1275-1280.
- **Yilmaz M.I., Sonmez A., Saglam M., Qureshi A., Carrero J.J., Caglar K., Eyileten T., Cakir E., Oguz Y., Vural A., Yenicesu M., Lindholm B., Stenvinkel P., Axelsson J.** : Markedly elevated circulating asymmetric dimethyl-arginine (ADMA) levels in proteinuric patients with secondary amyloidosis correlate with endothelial dysfunction. Is protein turnover in nephrotic syndrome a novel CVD risk factor? *J. Am. Soc. Nephrol* 2008.
- **Zager PG, Nikolic J, Brown RH, et al.** : “U” curve association of blood pressure and mortality in hemodialysis patients. *Medical Directors of Dialysis Clinic, Inc.* *Kidney Int* 1998;54:561-569.

- **Zannad F., Kessler M., Leheret P., Grunfeld J.P., Thuilliez C., Leizorovicz A., Lechat P.** : Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. *Kidney Int* 70: 1318–1324, 2006.
- **Zannetti S., L'Italien G.J. and Cambria R.P.** : Functional outcome after surgical treatment for intermittent claudication. *J. Vase Surg* 1996; 24: 65.
- **Zhang L., Du J., Hu Z., Han G., Delafontaine P., Garcia G., Mitch W.E.** : IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. *J. Am. Soc. Nephrol* 20: 604-612, 2009.
- **Zoccali C., Maas R., Cutrupi S., Pizzini P., Finocchiaro P., Cambareri F., Panuccio V., Martorao C., Schulze F., Enia G., Tripepi G., Boyer R.** : Asymmetric dimethylarginine (ADMA) response to inflammation in acute infections. *Nephrol Dial Transpl* 22: 801-806, 2007.
- **Zucehelli P. and Santoro A.** : Dialysis-induced hypotension: a fresh look at pathophysiology. *Blood Purif* 1993; 11:85-98.